Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 14376 - 14400 of 14497 in total
Experimental
Experimental
Experimental
A nicotinic cholinergic antagonist often referred to as the prototypical ganglionic blocker. It is poorly absorbed from the gastrointestinal tract and does not cross the blood-brain barrier. It has been used for a variety of therapeutic purposes including hypertension but, like the other ganglionic blockers, it has been replaced by...
Experimental
Matched Description: … It is poorly absorbed from the gastrointestinal tract and does not cross the blood-brain barrier. …
Experimental
Experimental
Vet approved
Experimental
XMT-1001 is a polymer-based prodrug of camptothecin (CPT), a well-characterized topoisomerase I inhibitor with potent anti-tumor activity. It is a water-soluble macromolecular conjugate of camptothecin (CPT). In this novel CPT pro-drug, CPT is conjugated with a 70 kDa biodegradable hydrophilic polyacetal, poly (1-hydroxymethylene hydroxylmethylformal). XMT-1001 has demonstrated an improved therapeutic...
Investigational
Matched Description: … XMT-1001 has demonstrated an improved therapeutic window as compared with CPT and irinotecan in human …
Nelotanserin has been used in trials studying the treatment of Lewy Body Dementia, Visual Hallucinations, Dementia With Lewy Bodies, and REM Sleep Behavior Disorder. It is a highly selective antagonist at the 5-HT2A serotonin receptor. It increases non-REM sleep, the most restorative phase of the sleep cycle, without sacrificing REM...
Investigational
Matched Description: … trials studying the treatment of Lewy Body Dementia, Visual Hallucinations, Dementia With Lewy Bodies, and
ABT-384 has been used in trials studying the treatment of Alzheimer's Disease.
Investigational
Urapidil has been investigated for the treatment of Hypertension During Pre-Eclampsia.
Investigational
Lifirafenib is under investigation in clinical trial NCT03641586 (The Study of BGB-283 in Chinese Subjects With Local Advanced or Metastatic Malignant Solid Tumor).
Investigational
This compound belongs to the nitrofurans. These are compounds containing a furan ring which bears a nitro group. It targets the protein aldose reductase.
Experimental
AMG-131 (T131), an orally-administered therapy, is expected to lower blood glucose in type II diabetic patients by improving the body’s ability to respond to insulin. T131 is a selective modulator of PPARg (peroxisome proliferator activated receptor gamma), a receptor involved in regulating the body’s ability to respond to insulin. T131...
Investigational
Matched Description: … is not structurally related to the thiazolidinedione class of PPARg agonists, which includes Actos and
Displaying drugs 14376 - 14400 of 14497 in total